Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

Inclusion Criteria:

* Histologically confirmed hematological disease, including any of the following:

  * Chronic lymphocytic leukemia

    * Absolute lymphocytosis \> 5,000/µL
    * Morphologically mature lymphocytes with \< 55% prolymphocytes
    * Lymphocyte phenotype with expression of CD19 and CD5
    * Absence of CD23 expression allowed provided disease is morphologically distinguished from mantle cell lymphoma
  * Prolymphocytic leukemia

    * Absolute lymphocytosis \> 5,000/µL
    * Morphologically mature lymphocytes with \> 55% prolymphocytes
  * Non-Hodgkin's or Hodgkin's lymphoma

    * Any WHO classification histologic subtype
    * Diagnosis by core biopsy allowed provided there is adequate tissue for diagnosis and immunophenotyping
    * Diagnosis by bone marrow biopsy not acceptable for follicular lymphomas
  * Multiple myeloma

    * Has received ≥ 1 prior treatment regimen
    * Has a partial response or greater by the Blade Criteria
    * Patients who achieved complete remission are eligible
  * Acute myeloid leukemia

    * Documented control (i.e., \< 10% bone marrow blasts and no circulating blasts)
  * Myelodysplastic syndromes

    * Documented disease as defined by WHO or French-American-British Cooperative group criteria
    * Chronic myelogenous leukemia
  * Patients with atypical chronic myelogenous leukemia (i.e., absent Philadelphia chromosome) are eligible
  * Polycythemia vera

    * Documented disease as defined by WHO criteria (i.e., A1 + A2, and any other category A, OR A1 + A2, and any 2 category B):

      * A1: Total red blood cell mass \> 25% above mean normal predicted value OR hemoglobin \> 18.5 g/dL in males, 16.5 g/dL in females (hematocrit ≥ 60% in males or ≥ 56% in females)
      * A2: No cause of secondary erythrocytosis (absence of familial erythrocytosis, no elevation of epoetin alfa \[EPO\] due to hypoxia, high oxygen affinity hemoglobin, truncated EPO receptor, or inappropriate ectopic EPO production)
      * A3: Splenomegaly
      * A4: Clonal genetic abnormality other than the Philadelphia chromosome
      * A5: Endogenous erythroid colony formation in vitro
      * B: Platelet count \> 400,000/mm³, WBC \> 12,000/mm³, bone marrow biopsy with prominent erythroid and megakaryocytic proliferation, and low serum EPO
  * Chronic idiopathic myelofibrosis

    * Documented disease as defined by WHO criteria
    * Must have a HLA-identical donor, a matched unrelated donor, or a HLA 9/10 related donor meeting the following criteria:
    * HLA-identical sibling (6/6)

      * Serologic typing for class I (A, B)
      * Molecular typing for class II (DRB1)
    * 9/10 matched related donor

      * High-resolution molecular typing at HLA-A, B, C, DRB1, and DQB1
      * Only a single mismatch at one class I or II allele allowed
    * 10/10 matched unrelated donor

      * Molecular identity at HLA-A, B, C, DRB1, and DQB1 by high-resolution typing
      * Syngeneic donors are not eligible
* Creatinine clearance ≥ 40 mL/min
* Bilirubin ≤ 3 times upper limit of normal (ULN)
* AST ≤ 3 times ULN
* DLCO ≥ 40% with no symptomatic pulmonary disease
* LVEF ≥ 30% by cardiac MRI or echocardiogram with no symptomatic cardiac disease
* Fertile patients willing to use effective contraception

Exclusion Criteria:

* Uncontrolled diabetes mellitus
* Active serious infection
* Known hypersensitivity to E. coli-derived products
* Known HIV positivity
* History of another malignancy\*, meeting the following criteria:

  * Non-skin malignancy or melanoma within the past 5 years
  * Concomitant malignancy that has not been curatively treated
  * NOTE: \*However, cancer survivors who have undergone potentially curative therapy for a prior malignancy at least 5 years before enrollment and are deemed at low risk of \< 30% for recurrence by their treating physicians is considered
* Pregnant or nursing